Pharmaceuticals company GlaxoSmithKline Pharmaceuticals announced Q2FY26 results Revenue from Operations was Rs 974 crore for Q2FY26. EBIDTA margins for Q2FY26 stood at 34.4%, growth 250 bps. Profit After Tax (PAT) was Rs 255 crore for Q2FY26. Bhushan Akshikar, Managing Director, GSK India, said: “Within two months of launch, our Oncology portfolio is impacting patients by addressing a critical unmet need in gynaecological cancers in India. Together, these assets represent meaningful progress in women’s cancer care. Moving ahead, we remain focused on ensuring that cutting-edge innovative treatments are both available and accessible to those who need them the most, supported by our comprehensive patient support and financing initiatives.” Result PDF